Active Ingredient(s): Glycopyrronium Tosylate
FDA Approved: * June 28, 2018
Pharm Company: * DERMIRA INC
Category: Anticholinergic

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Qbrexza Overview

Glycopyrronium bromide is a medication of the muscarinic anticholinergic group. It does not cross the blood–brain barrier and consequently has few to no central effects. It is available in oral, intravenous, topical, and inhaled forms. It is a synthetic quaternary ammonium compound. The cation, which is the active moiety, is called glycopyrronium (INN)[1] or glycopyrrolate (USAN). In June 2018, glycopyrronium was approved by the FDA to treat excessive underarm sweating,...

Read more Qbrexza Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Glycopyrronium_bromide

Recent Qbrexza Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Glycopyrronium Tosylate
  • Cloth: 2.4%
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Qbrexza: (2 results)

Sorted by National Drug Code
  • 69489-411 Qbrexza 2.4 g/100g Topical Cloth by Journey Medical Corporation
  • 70428-011 Qbrexza 2.4 g/100g Topical Cloth by Dermira, Inc.

Other drugs which contain Glycopyrronium Tosylate or a similar ingredient: (1 result)